<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Acquired thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="1" ids="18284">TTP</z:chebi>), characterized by widespread <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the microcirculation, is a ponderous complication of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor-cleaving protease (VWF-CPase) activity has been reported as a possible determinant for the occurrence of <z:chebi fb="1" ids="18284">TTP</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>To clarify the role of VWF-CPase in the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation associated with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, we investigated plasma VWF-CPase activity in patients of <z:e sem="disease" ids="C0748408,C0009326" disease_type="Disease or Syndrome" abbrv="">collagen diseases</z:e> with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) </plain></SENT>
<SENT sid="3" pm="."><plain>Decreased plasma VWF-CPase activity less than 50% of the <z:mpath ids='MPATH_458'>normal</z:mpath> activity was observed in 25.7% (n = 18) in 70 patients with <z:e sem="disease" ids="C0748408,C0009326" disease_type="Disease or Syndrome" abbrv="">collagen diseases</z:e> and 7 (10%) cases of them showed more lower VWF-CPase activity less than 25% </plain></SENT>
<SENT sid="4" pm="."><plain>The IgG fractions obtained from 2 patients with the low VWF-CPase activity strongly inhibited the proteolytic reaction of <z:mpath ids='MPATH_458'>normal</z:mpath> VWF-CPase </plain></SENT>
<SENT sid="5" pm="."><plain>There was no significant relationship between LA and plasma VWF-CPase activity </plain></SENT>
<SENT sid="6" pm="."><plain>Thrombotic episodes, especially <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, were more frequently observed in LA-positive patients with low VWF-CPase activity </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that decreased activity of VWF-CPase, partly due to IgG type inhibitor to the enzyme activity may be an additional risk factor for <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> in <z:e sem="disease" ids="C0748408,C0009326" disease_type="Disease or Syndrome" abbrv="">collagen disease</z:e> patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
</text></document>